AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
PMV Pharmaceuticals Posts Q1 GAAP EPS of -$0.34, Exceeding Expectations by $0.03, with $165.8 Million in Cash and Marketable Securities as of March 31, 2025.
ByAinvest
Friday, May 9, 2025 9:59 am ET1min read
PMV Pharmaceuticals reported Q1 GAAP EPS of -$0.34, beating estimates by $0.03. The company had cash, cash equivalents, and marketable securities of $165.8 million as of March 31, 2023, providing a cash runway to end of 2026.
PMV Pharmaceuticals, Inc. (PMVP) reported its first-quarter 2025 financial results, showcasing a quarterly adjusted earnings per share (EPS) of -$0.34, which exceeded market expectations by $0.03. The company's cash, cash equivalents, and marketable securities stood at $165.8 million as of March 31, 2025, providing a cash runway until the end of 2026 [1].The company's net loss for the quarter ended March 31, 2025, was $17.5 million compared to $15.3 million for the same period in 2024. Operating expenses reached $21.564 million, with research and development (R&D) expenses totaling $17.4 million, an increase of $4.2 million from the same period last year. General and administrative (G&A) expenses decreased to $4.1 million from $5.0 million in the same quarter last year [2].
PMV Pharma's interim analysis from the Phase 2 PYNNACLE clinical trial is expected in the middle of 2025, including data for approximately 50 patients. The trial is evaluating rezatapopt (PC14586) as a monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors. The company's co-founder, Dr. Arnold Levine, established the field of p53 biology, and PMV Pharma continues to build on this foundation with its precision oncology focus [2].
The company's cash balance of $165.8 million as of March 31, 2025, provides a strong financial position, supporting ongoing clinical trials and product development. PMV Pharma's strategic focus on small molecule, tumor-agnostic therapies targeting p53 mutations positions it as a leader in precision oncology [2].
References:
[1] https://www.tradingview.com/news/reuters.com,2025-05-09:newsml_PLX29B2E8:0-brief-pmv-pharmaceuticals-q1-eps-usd-0-34/
[2] https://www.globenewswire.com/news-release/2025/05/09/3078214/0/en/PMV-Pharmaceuticals-Reports-First-Quarter-2025-Financial-Results-and-Corporate-Highlights.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet